Sidoris Biomedical, an AMI subsidiary, Announces Successful Anastomosis Achieved Using Novel Bioresorbable Circular Staples in Ongoing Animal Studies

BOSTON, Jan. 16, 2018 /PRNewswire/ -- Sidoris Biomedical has announced that successful anastomosis was achieved using internal circular staples fabricated with BioDG Inc.'s proprietary bioresorbable metal in ongoing animal studies.

The patented metal, developed by BioDG, is designed to bioabsorb from the outside in, maintaining its strength during the healing process, and biodegrade safely over time. It was formulated to match the characteristics of titanium or stainless steel.

The studies involved four pigs. In all cases, the staples were successfully fired and performed identically to titanium staples. Anastomosis was achieved with no air leaks. There were no foreign body reactions or toxicity issues in any of the pigs.

"This is a major advancement in staple technology and surgical implants," said Anthony Senagore, MD, MS, MBA, professor and vice chair for clinical operations at the University of Texas Medical Branch. "Having a staple that biodegrades safely after healing will help reduce complications, and leave no foreign body behind after colorectal surgery procedures."

The studies, conducted on December 11 and 18, 2017 at Washington University School of Medicine in St. Louis, were designed to demonstrate the safety and efficacy of the metal, compare its performance to titanium staples, and determine the underlying rate of dissolution of the metal. The dissolution rate will be verified at various intervals starting January 18, 2018.

Sidoris is actively pursuing exclusive licensing of BioDG's resorbable metal for surgical staples, ligation and surgical mesh. For more information, please contact Warren Pelissier at [email protected] or 781-749-9290.

About Sidoris
Sidoris Biomedical LLC provides healthcare industry leading companies access to next generation products that harness BioDG's proprietary bioresorbable metal technology.

About BioDG
BioDG, Inc. Has pioneered bioresorbable metal technology that can be customized to meet specific clinical challenges. The company's bioresorbable metals are engineered to provide the necessary structural support for the required clinical duration and then gradually dissolve safely over time.

About AMI
Advancing Medical Innovation, Inc. was formed to help start-up companies with young technologies establish proof of concept and demonstrate clinical value. The company plays an active role in selling and licensing innovations to industry partners.

Contact:
Warren Pelissier
[email protected] 
781-749-9290

SOURCE AMI